This trial studies safety & effectiveness of a new COPD treatment. Subjects may be offered a chance to join an extension study.
- Chronic Obstructive Pulmonary Disease (COPD)
1 Primary · 7 Secondary · Reporting Duration: 104 weeks total (52 weeks in this study)
3 Treatment Groups
Tozorakimab Dose 1
1 of 3
Tozorakimab Dose 2
1 of 3
1 of 3
2544 Total Participants · 3 Treatment Groups
Primary Treatment: Tozorakimab Dose 1 · Has Placebo Group · Phase 3
Who is running the clinical trial?
Age 40 - 130 · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is the age range for this trial limited, and if so what are its upper limits?
"Adhering to the parameters of entry, individuals aged 40 and over but less than 130 can enroll in this medical trial." - Anonymous Online Contributor
How hazardous is the first dosage of Tozorakimab for patients?
"Our evaluations place Tozorakimab Dose 1's safety at 3, due to the presence of multiple rounds of data confirming efficacy and supporting data for its security." - Anonymous Online Contributor
In what geographical areas can this clinical trial be accessed?
"This study is currently enrolling patients at 10 sites, including the cities of Newport Beach, Pensacola and Tampa. To reduce travel requirements for potential participants, it may be prudent to choose a medical site close by." - Anonymous Online Contributor
Are there any remaining openings in this clinical research endeavor?
"As detailed on clinicaltrials.gov, this clinical trial has stopped recruiting participants at present. Initially posted on February 20th 2023 and last updated on the 15th of that same month, there are 472 other research studies actively seeking patients to join their trials right now." - Anonymous Online Contributor
Are there any criteria restricting participation in this experiment?
"This medical study is enrolling 2544 individuals aged 40 to 130 with chronic obstructive pulmonary disease. To be considered, applicants must have completed the treatment period of predecessor studies within 12 weeks prior and provide a negative urine pregnancy test result. Additionally, female participants need to attest that they are using contraception as agreed in earlier trials before being accepted into this research program. Ultimately, all potential participants must sign an informed consent document to qualify for involvement." - Anonymous Online Contributor